These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 16445979)

  • 21. An investigator-masked comparison of the efficacy and safety of twice daily applications of calcitriol 3 microg/g ointment vs. calcipotriol 50 microg/g ointment in subjects with mild to moderate chronic plaque-type psoriasis.
    Zhu X; Wang B; Zhao G; Gu J; Chen Z; Briantais P; Andres P
    J Eur Acad Dermatol Venereol; 2007 Apr; 21(4):466-72. PubMed ID: 17373972
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies.
    Lebwohl M; Menter A; Weiss J; Clark SD; Flores J; Powers J; Balin AK; Kempers S; Glinert RJ; Fleming T; Liu Y; Graeber M; Pariser DM
    J Drugs Dermatol; 2007 Apr; 6(4):428-35. PubMed ID: 17668541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer.
    Dittrich C; Petruzelka L; Vodvarka P; Gneist M; Janku F; Kysela T; Melemed A; Latz J; Simms L; Krejcy K
    Clin Cancer Res; 2006 Dec; 12(23):7071-8. PubMed ID: 17145830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pilot study of priming with granulocyte macrophage colony-stimulating factor plus all-trans retinoic acid combined with remission induction chemotherapy in patients with acute myeloid leukemia.
    Shin HJ; Chung JS; Choi YJ; Cho GJ
    Am J Clin Oncol; 2009 Jun; 32(3):227-32. PubMed ID: 19433969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of anthracycline-based combination chemotherapy with or without all-trans retinoic acid in acute promyelocytic leukemia.
    Raza S; Ullah K; Ahmed P; Khan B
    J Coll Physicians Surg Pak; 2008 Sep; 18(9):546-50. PubMed ID: 18803891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
    Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
    Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.
    Popat R; Oakervee H; Williams C; Cook M; Craddock C; Basu S; Singer C; Harding S; Foot N; Hallam S; Odeh L; Joel S; Cavenagh J
    Br J Haematol; 2009 Mar; 144(6):887-94. PubMed ID: 19183191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hereditary angioedema: Safety of long-term stanozolol therapy.
    Sloane DE; Lee CW; Sheffer AL
    J Allergy Clin Immunol; 2007 Sep; 120(3):654-8. PubMed ID: 17765757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer.
    Liu ZF; Guo QS; Zhang XQ; Yang XG; Guan F; Fu Z; Wang MY
    Am J Clin Oncol; 2008 Jun; 31(3):259-63. PubMed ID: 18525305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
    Tsimberidou AM; Wierda WG; Plunkett W; Kurzrock R; O'Brien S; Wen S; Ferrajoli A; Ravandi-Kashani F; Garcia-Manero G; Estrov Z; Kipps TJ; Brown JR; Fiorentino A; Lerner S; Kantarjian HM; Keating MJ
    J Clin Oncol; 2008 Jan; 26(2):196-203. PubMed ID: 18182662
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer.
    Caponigro F; Lacombe D; Twelves C; Bauer J; Govaerts AS; Marréaud S; Milano A; Anthoney A
    Eur J Cancer; 2009 Jan; 45(1):48-55. PubMed ID: 18809314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.
    Berenson JR; Yang HH; Vescio RA; Nassir Y; Mapes R; Lee SP; Wilson J; Yellin O; Morrison B; Hilger J; Swift R
    Ann Hematol; 2008 Aug; 87(8):623-31. PubMed ID: 18463870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.
    Berenson JR; Matous J; Swift RA; Mapes R; Morrison B; Yeh HS
    Clin Cancer Res; 2007 Mar; 13(6):1762-8. PubMed ID: 17363530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of combination chemotherapy with mitomycin and vinorelbine for the treatment of advanced non-small cell lung cancer.
    Wibmer T; Kropf C; Merk T; Schumann C; Hombach V; Krüger S
    Lung Cancer; 2008 May; 60(2):231-9. PubMed ID: 18006111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term efficacy and safety of quadruple therapy in childhood diffuse proliferative lupus nephritis.
    Demircin G; Oner A; Erdoğan O; Delibaş A; Baysun S; Bülbül M; Bek K; Oksal A
    Ren Fail; 2008; 30(6):603-9. PubMed ID: 18661410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias.
    Rao A; Kelly M; Musselman M; Ramadas J; Wilson D; Grossman W; Shenoy S
    Pediatr Blood Cancer; 2008 Apr; 50(4):822-5. PubMed ID: 17570702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retinoic acid therapy in "degenerative-like" neuro-langerhans cell histiocytosis: a prospective pilot study.
    Idbaih A; Donadieu J; Barthez MA; Geissmann F; Bertrand Y; Hermine O; Brugières L; Genereau T; Thomas C; Hoang-Xuan K
    Pediatr Blood Cancer; 2004 Jul; 43(1):55-8. PubMed ID: 15170890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term efficacy of danazol treatment in hereditary angioedema.
    Füst G; Farkas H; Csuka D; Varga L; Bork K
    Eur J Clin Invest; 2011 Mar; 41(3):256-62. PubMed ID: 20955212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Androgen in the treatment of refractory anemia.
    Kobaba R; Kanamaru A; Takemoto Y; Kohsaki M; Kakishita E; Nagai K
    Int J Hematol; 1991 Apr; 54(2):103-7. PubMed ID: 1747444
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical report on treatment of 7 patients with refractory anemia by using cyclosporin A].
    Kong XR; Feng YM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Oct; 12(5):697-8. PubMed ID: 15498138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.